AZ13705339

| Cat. No.: | HY-120940 | | | | |
|--------------------|--|-------|----------|--|--|
| CAS No.: | 2016806-57-6 | | | | |
| Molecular Formula: | C ₃₃ H ₃₆ FN ₇ O ₃ S | | | | |
| Molecular Weight: | 629.75 | | | | |
| Target: | РАК | | | | |
| Pathway: | Cell Cycle/DNA Damage; Cytoskeleton | | | | |
| Storage: | Powder | -20°C | 3 years | | |
| | In solvent | -80°C | 6 months | | |
| | | -20°C | 1 month | | |

®

MedChemExpress

SOLVENT & SOLUBILITY

| | Mass Solvent Concentration | 1 mg | 5 mg | 10 mg |
|------------------------------|----------------------------------|-----------|-----------|------------|
| Preparing Stock Solutions | 1 mM | 1.5879 mL | 7.9397 mL | 15.8793 ml |
| | 5 mM | 0.3176 mL | 1.5879 mL | 3.1759 mL |
| | 10 mM | 0.1588 mL | 0.7940 mL | 1.5879 mL |

| DIOLOGICAL ACTIVITY | | | | | | | |
|---------------------------|--|----------------------|-------------------------------------|------------------------------------|--|--|--|
| Description | AZ13705339 is a highly potent and selective PAK1 inhibitor with IC ₅₀ s of 0.33 nM and 59 nM for PAK1 and pPAK1, respectively. AZ13705339 has binding affinities to PAK1 and PAK2, with K _d s of 0.28 nM and 0.32 nM, respectively. AZ13705339 can be used in the research of cancers ^[1] . | | | | | | |
| IC ₅₀ & Target | PAK2 0.32 nM (Kd) | PAK1 0.28 nM (Kd) | PAK1 0.33 nM (IC ₅₀) | pPAK1 59 nM (IC ₅₀) | | | |
| In Vitro | AZ13705339 (1 μM) inhibits αlgM-controlled adhesion and not PMA-induced adhesion in Namalwa cells ^[2] . AZ13705339 (300 nM, 30 min) prevents Siglec-8 engagement-induced eosinophil death ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. | | | | | | |
| In Vivo | AZ13705339 (100 mg/kg, P.O.) has moderate clearance and oral C _{max} of 7.7 μM in rats ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. | | | | | | |

Product Data Sheet

HO

[1]. McCoull W, Hennessy EJ, Blades K, et al. Optimization of Highly Kinase Selective Bis-anilino Pyrimidine PAK1 Inhibitors. ACS Med Chem Lett. 2016;7(12):1118-1123. Published 2016 Sep 14.

[2]. Martin F M de Rooij, et al. A loss-of-adhesion CRISPR-Cas9 screening platform to identify cell adhesion-regulatory proteins and signaling pathways. Nat Commun. 2022 Apr 19;13(1):2136.

[3]. Daniela J Carroll, et al. Siglec-8 Signals Through a Non-Canonical Pathway to Cause Human Eosinophil Death In Vitro. Front Immunol. 2021 Oct 11;12:737988.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA